COVID-19 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): a propensity matched analysis (2020-2021)

COVID-19 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): a propensity matched analysis (2020-2021)

BackgroundBy 2023, COVID-19 had caused 6.8 million deaths in the United States. COVID-19 presents more severely in leukemia compared to solid tumors (OR 1.6, p<0.05). However, data on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) are limited. We investigated the mortality in...

Full description

Bibliographic Details
Main Authors: Barath Prashanth Sivasubramanian, Shashvat Joshi, Diviya Bharathi Ravikumar, Madhumithaa Jagannathan, Sonia Babu, Shanthi Reddy Sripathi, Avinash Javvaji, Priyanshu Jain, Dinesh Kumar Shanmugam, Bharath Duraisamy Swami Kannan, Raghavendra Tirupathi, Rutul Dalal
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-10-01
Series:Frontiers in Oncology
Subjects:
AML
myelodysplastic syndrome
COVID-19
severe sepsis
ARDS
acute respiratory failure
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1446482/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1446482/full

Similar Items